Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 16, 2018 - Issue 7
Submit an article Journal homepage
2,992
Views
34
CrossRef citations to date
0
Altmetric
Original Research

The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study

Marcello ArcaDepartment of Lipid and Atherosclerosis, La Sapienza University of Rome, Rome, ItalyView further author information
,
Andrew HsiehAkcea Therapeutics, Cambridge, MA, USAView further author information
,
Handrean SoranDepartment of Medicine, Manchester University Hospital NHS Foundation Trust, Manchester, UKView further author information
,
Paul RosenblitDivision of Endocrinology, University of California, Irvine, Irvine, CA and Diabetes/Lipid Management & Research Center, Huntington Beach, CA, USAView further author information
,
Louis O’DeaAkcea Therapeutics, Cambridge, MA, USAView further author information
&
Michael StevensonAkcea Therapeutics, Cambridge, MA, USACorrespondence[email protected]
View further author information
Pages 537-546 | Received 27 Mar 2018, Accepted 07 Jun 2018, Published online: 22 Jun 2018

Citations (34)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Isabel Shamsudeen & Robert A. Hegele. (2022) Safety and efficacy of therapies for chylomicronemia. Expert Review of Clinical Pharmacology 15:4, pages 395-405.
Read now
Julieta Lazarte & Robert A. Hegele. (2021) Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Review of Cardiovascular Therapy 19:8, pages 685-693.
Read now
Oluwayemisi Esan & Anthony S Wierzbicki. (2020) Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy. Drug Design, Development and Therapy 14, pages 2623-2636.
Read now
Laura D’Erasmo, Antonio Gallo, Alessia Di Costanzo, Eric Bruckert & Marcello Arca. (2020) Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. Expert Opinion on Pharmacotherapy 21:14, pages 1675-1684.
Read now
Rina S. Fox, John Devin Peipert, Montserrat Vera-Llonch, Glenn Phillips & David Cella. (2020) PROMIS® and Neuro-QoLTM measures are valid measures of health-related quality of life among patients with familial chylomicronemia syndrome. Expert Review of Cardiovascular Therapy 18:4, pages 231-238.
Read now
David Rhainds, Mathieu R. Brodeur & Jean-Claude Tardif. (2019) Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. Expert Opinion on Investigational Drugs 28:12, pages 1059-1079.
Read now
Dimitrios Milonas & Konstantinos Tziomalos. (2019) Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia – spotlight on volanesorsen. Expert Opinion on Investigational Drugs 28:4, pages 389-394.
Read now
Marilisa Bove, Arrigo F.G. Cicero & Claudio Borghi. (2019) Emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs 24:1, pages 63-69.
Read now

Articles from other publishers (26)

Iveta Merćep, Andro Vujević, Dominik Strikić, Ivana Radman, Ivan Pećin & Željko Reiner. (2023) Present and Future of Dyslipidaemia Treatment—A Review. Journal of Clinical Medicine 12:18, pages 5839.
Crossref
Maria Cristina de Oliveira Izar, Raul Dias dos SantosFilhoFilho, Marcelo Heitor Vieira Assad, Antonio Carlos Palandri Chagas, Alceu de Oliveira ToledoJúniorJúnior, Ana Cláudia Cavalcante Nogueira, Ana Cristina Carneiro Fernandes Souto, Ana Maria Pitta Lottenberg, Ana Paula Marte Chacra, Carlos Eduardo dos Santos Ferreira, Charles Marques Lourenço, Cynthia Melissa Valerio, Dennys Esper Cintra, Francisco Antonio Helfenstein Fonseca, Gustavo Aguiar Campana, Henrique Tria Bianco, Josivan Gomes de Lima, Maria Helane Costa Gurgel Castelo, Marileia Scartezini, Miguel Antonio Moretti, Natasha Slhessarenko Fraife Barreto, Rayana Elias Maia, Renan Magalhães MontenegroJuniorJunior, Renato Jorge Alves, Roberta Marcondes Machado Figueiredo, Rodrigo Ambrosio Fock & Tânia Leme da Rocha Martinez. (2023) Posicionamento Brasileiro sobre Síndrome da Quilomicronemia Familiar – 2023. Arquivos Brasileiros de Cardiologia 120:4.
Crossref
Daniele Tramontano, Simone Bini, Laura D’Erasmo & Marcello Arca. (2022) Recent Apolipoprotein CIII trials. Current Opinion in Lipidology 33:6, pages 309-318.
Crossref
Ilenia Calcaterra, Roberta Lupoli, Alessandro Di Minno & Matteo Nicola Dario Di Minno. (2022) Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials. European Journal of Clinical Investigation 52:11.
Crossref
Karen Kaiser, Rina S. Fox, Chelsea Perschon, Montserrat Vera-Llonch, Jordi Alonso, Laia Cubells & David Cella. (2022) Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28. Quality of Life Research.
Crossref
Maria Monticelli, Rita Francisco, Sandra Brasil, Dorinda Marques-da-Silva, Tatiana Rijoff, Carlota Pascoal, Jaak Jaeken, Paula A. Videira & Vanessa dos Reis Ferreira. (2022) Stakeholders’ views on drug development: the congenital disorders of glycosylation community perspective. Orphanet Journal of Rare Diseases 17:1.
Crossref
Clarice Gareri, Alberto Polimeni, Salvatore Giordano, Laura Tammè, Antonio Curcio & Ciro Indolfi. (2022) Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. Journal of Clinical Medicine 11:13, pages 3884.
Crossref
Genovefa Kolovou, Vana Kolovou & Niki Katsiki. (2022) Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia. Journal of Clinical Medicine 11:4, pages 982.
Crossref
Matthew Gesner & William H. Frishman. (2022) Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome. Cardiology in Review Publish Ahead of Print.
Crossref
Inês Colaço, Francisco Araújo, Patrício Aguiar, Diogo Cruz, Mafalda Bourbon, João Sequeira Duarte & Manuel Teixeira Veríssimo. (2021) Síndrome de Quilomicronemia Familiar: Algoritmo Diagnóstico. Medicina Interna 28:4, pages 369-377.
Crossref
Xiaoming Jia, Jing Liu, Anurag Mehta, Christie M. Ballantyne & Salim S. Virani. (2020) Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective. Cardiovascular Drugs and Therapy 35:6, pages 1269-1279.
Crossref
Ioannis Akoumianakis, Evangelia Zvintzou, Kyriakos Kypreos & Theodosios D. Filippatos. (2021) ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Current Atherosclerosis Reports 23:5.
Crossref
Cinzia Parolini. (2020) Biotechnology Approaches for the Treatment of Dyslipidemia. Cardiovascular Drugs and Therapy 35:1, pages 167-183.
Crossref
Lynnetta M. WattsEwa Karwatowska-ProkopczukEunju HurhVeronica J. AlexanderKristin BaloghLouis O'DeaRichard S. GearySotirios Tsimikas. (2020) Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers . Nucleic Acid Therapeutics 30:4, pages 198-206.
Crossref
Federica Fogacci, Giuseppe Danilo Norata, Peter P. Toth, Marcello Arca & Arrigo F. G. Cicero. (2020) Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Current Atherosclerosis Reports 22:5.
Crossref
Ulrich Laufs, Klaus G Parhofer, Henry N Ginsberg & Robert A Hegele. (2020) Clinical review on triglycerides. European Heart Journal 41:1, pages 99-109c.
Crossref
Emile Levy, Valérie Marcil & Edgard Delvin. 2020. Encyclopedia of Gastroenterology. Encyclopedia of Gastroenterology 170 179 .
Tejal Aslesh & Toshifumi Yokota. 2020. Gapmers. Gapmers 69 85 .
C. Macchi, C.R. Sirtori, A. Corsini, R.D. Santos, G.F. Watts & M. Ruscica. (2019) A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacological Research 150, pages 104413.
Crossref
Constantine E Kosmas, Andreas Sourlas, Delia Silverio, Peter D Montan & Eliscer Guzman. (2019) Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease. World Journal of Cardiology 11:11, pages 256-265.
Crossref
Julia Paik & Sean Duggan. (2019) Volanesorsen: First Global Approval. Drugs 79:12, pages 1349-1354.
Crossref
L Renee Ruhaak, Arnoud van der Laarse & Christa M Cobbaert. (2019) Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 56:3, pages 338-356.
Crossref
Ernst J. Schaefer, Andrew S. Geller & Gregory Endress. (2019) The biochemical and genetic diagnosis of lipid disorders. Current Opinion in Lipidology 30:2, pages 56-62.
Crossref
Robert A. HegeleSotirios Tsimikas. (2019) Lipid-Lowering Agents. Circulation Research 124:3, pages 386-404.
Crossref
O. I. Afanasieva, M. V. Ezhov & S. N. Pokrovsky. (2018) ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTICAL MONOCLONAL ANTIBODIES AS A BASEMENT FOR NOVEL BIOLOGICAL LIPIDLOWERING DRUGS. Russian Journal of Cardiology:8, pages 99-109.
Crossref
Željko Reiner. (2018) Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circulation Journal 48:12, pages 1097.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.